Atrion Revenue Growth Rates (ATRI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Atrion Corporation  (NASDAQ: ATRI)
 

ATRI's Revenue Growth by Quarter and Year

Atrion's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ATRI Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June 48.77
1st Quarter March 47.33
FY 96.10

ATRIs Annual Revenue
Atrion's Revenue in the fiscal year 2023 $ 169.33 millions
Atrion's Revenue in the fiscal year 2022 $ 183.51 millions
Atrion's Revenue in the fiscal year 2020 $ 147.59 millions
Atrion's Revenue in the fiscal year 2019 $ 155.07 millions
Atrion's Revenue in the fiscal year 2018 $ 152.45 millions




ATRI Revenue second quarter 2024 Y/Y Growth Comment
Atrion Corporation achieved in the second quarter 2024, above Company average Revenue increase of 11.25% year on year, to $ 48.77 millions.

Looking into second quarter 2024 results within Medical Equipment & Supplies industry 77 other companies have achieved higher Revenue growth. While Atrion Corporation' s Revenue growth of 11.25% ranks overall at the positon no. 1250 in the second quarter 2024.


ATRI Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 1.68 % 6.38 % 24.97 %
3rd Quarter September - -6.09 % 4.13 % 26.84 %
2nd Quarter June 11.25 % -10.31 % 14.5 % 12.43 %
1st Quarter March 18.35 % -15.17 % 20.35 % -10.14 %
FY   - -7.73 % 11.21 % -

Financial Statements
Atrion's second quarter 2024 Revenue $ 48.77 millions ATRI's Income Statement
Atrion's second quarter 2023 Revenue $ 43.84 millions Quarterly ATRI's Income Statement


ATRI Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 3.98 % -3.97 % -6 %
3rd Quarter September - -4.4 % -8.69 % 0.4 %
2nd Quarter June 3.05 % 9.63 % 3.69 % 8.99 %
1st Quarter March 8.6 % -6.7 % 17 % 21.5 %
FY (Year on Year)   - -7.73 % 11.21 % -


Back to ATRI Growth rate Comparisons >> Back to ATRI Growth rate Comparisons >>


Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #78
Healthcare Sector #290
Overall #1250

Revenue Y/Y Growth Statistics
High Average Low
41.21 % 4.29 % -15.16 %
(Dec 31 2022)   (Mar 31 2023)
Revenue second quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #78
Healthcare Sector #290
Overall #1250
Revenue Y/Y Growth Statistics
High Average Low
41.21 % 4.29 % -15.16 %
(Dec 31 2022)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Atrion's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
55.32 % 1.36 % -29.18 %
(Mar 31 2022)  


ATRI's II. Quarter Q/Q Revenue Comment
Atrion Corporation achieved in the II. Quarter 2024 above company average sequential Revenue growth of 3.05%, to $ 48.77 millions, from $47.33 millions in the first quarter.

Within Medical Equipment & Supplies industry 115 other companies have achieved higher Revenue quarter on quarter growth. While Atrion's Revenue growth quarter on quarter, overall rank is 1981.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #116
Healthcare Sector #376
Overall #1981
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #116
Healthcare Sector #376
Overall #1981
Revenue Q/Q Growth Statistics
High Average Low
55.32 % 1.36 % -29.18 %
(Mar 31 2022)  


ATRI's II. Quarter Q/Q Revenue Comment
Atrion Corporation achieved in the II. Quarter 2024 above company average sequential Revenue growth of 3.05%, to $ 48.77 millions, from $47.33 millions in the first quarter.

Within Medical Equipment & Supplies industry 115 other companies have achieved higher Revenue quarter on quarter growth. While Atrion's Revenue growth quarter on quarter, overall rank is 1981.


Atrion's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)
Cumulative Revenue 12 Months Ending $ 181.60 $ 176.67 $ 169.33 $ 168.60 $ 171.32
Y / Y Revenue Growth (TTM) 6 % 0.17 % -7.73 % -6.82 % -4.38 %
Year on Year Revenue Growth Overall Ranking # 1285 # 397 # 764 # 1361 # 1110
Seqeuential Revenue Change (TTM) 2.79 % 4.34 % 0.43 % -1.59 % -2.86 %
Seq. Revenue Growth (TTM) Overall Ranking # 2406 # 827 # 1129 # 1898 # 1129


Cumulative Revenue growth Comment
Atrion saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 6% year on year, to $ 182 millions if the fiscal year would have ended in Jun 30 2024.
Atrion's trailing twelve months Revenue growth was higher than company's average 3.44% and higher than 0.17% growth in Mar 31 2024.
But from twelve months ended Mar 31 2024 rise was beneth at 2.79 % from $176.67 millions achieved in the period from Mar 31 2024 to Jun 30 2023.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at3.44%.
The momentum is even more impressive from twelve months ended Mar 31 2024 exhibited at 2.79 % increase from $176.67 millions in the period from Mar 31 2024 to Jun 30 2023.

In the Healthcare sector 271 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 397 to 1285.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 122
Healthcare Sector # 272
Overall # 1285

Revenue TTM Y/Y Growth Statistics
High Average Low
18.34 %
 3.44 %
-5.68 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 122
Sector # 376
S&P 500 # 2406
Cumulative Revenue growth Comment
Atrion saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 6% year on year, to $ 182 millions if the fiscal year would have ended in Jun 30 2024.
Atrion's trailing twelve months Revenue growth was higher than company's average 3.44% and higher than 0.17% growth in Mar 31 2024.
But from twelve months ended Mar 31 2024 rise was beneth at 2.79 % from $176.67 millions achieved in the period from Mar 31 2024 to Jun 30 2023.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at3.44%.
The momentum is even more impressive from twelve months ended Mar 31 2024 exhibited at 2.79 % increase from $176.67 millions in the period from Mar 31 2024 to Jun 30 2023.

In the Healthcare sector 271 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 397 to 1285.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 122
Healthcare Sector # 272
Overall # 1285

Revenue TTM Y/Y Growth Statistics
High Average Low
18.34 %
3.44 %
-5.68 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 122
Sector # 376
S&P 500 # 2406




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ATRI's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2024
Irhythm Holdings Inc 19.68%$ 19.676 millions
Biomarin Pharmaceutical Inc19.61%$ 19.613 millions
Ionis Pharmaceuticals Inc 19.55%$ 19.552 millions
Cadre Holdings inc 19.51%$ 19.514 millions
Novocure Limited19.28%$ 19.282 millions
Paragon 28 inc 19.11%$ 19.106 millions
Aim Immunotech Inc 19.05%$ 19.048 millions
Ani Pharmaceuticals Inc18.44%$ 18.441 millions
Glaukos Corp18.33%$ 18.335 millions
Vivos Therapeutics Inc 17.85%$ 17.850 millions
Procyon Corporation17.51%$ 17.513 millions
Bausch and Lomb Corp17.49%$ 17.488 millions
Bruker Corporation17.48%$ 17.476 millions
American Shared Hospital Services17.22%$ 17.216 millions
Amneal Pharmaceuticals Inc 17.15%$ 17.154 millions
Qhslab Inc 16.87%$ 16.875 millions
Cerus Corporation16.51%$ 16.506 millions
Veracyte Inc 16.15%$ 16.154 millions
Curis Inc 15.89%$ 15.885 millions
Scorpius Holdings inc 15.53%$ 15.532 millions
Mangoceuticals Inc 15.52%$ 15.524 millions
Integrated Biopharma Inc15.35%$ 15.352 millions
Maxcyte inc 15.33%$ 15.332 millions
Myriad Genetics Inc 15.26%$ 15.259 millions
P3 Health Partners Inc 15.22%$ 15.215 millions
Dexcom Inc 15.20%$ 15.196 millions
Butterfly Network Inc 14.86%$ 14.864 millions
Atricure Inc 14.79%$ 14.790 millions
Option Care Health Inc 14.71%$ 14.713 millions
Hyperfine Inc 14.69%$ 14.689 millions


About Atrion Revenue Growth Rates (ATRI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Atrion Corp (CIK 701288).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001654954-24-010185
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Atrion Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.